US FDA approves Verastem's Avmapki Fakzynja combo therapy to treat patients with KRAS─mutated recurrent low─grade serous ...
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced that the US Food and Drug Administration (FDA) has approved Avmapki Fakzynja Co-Pack (avutometinib capsules …